Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...

Pomalyst will be available in 1mg, 2mg, 3mg, and 4mg strength capsules in 21- and 100-count bottles. Pomalyst is expected to be available in about two weeks. Continue Reading.

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

Pomalyst appears to be on track to eventually hit annual sales between $1 billion and $2 billion. If that happens, the drug would by far eclipse the success of Thalomid.

Pomalyst appears to be on track to eventually hit annual sales between $1 billion and $2 billion. If that happens, the drug would by far eclipse the success of Thalomid.

Pomalyst is a prescription drug used to treat multiple myeloma and Kaposi sarcoma. Learn about the drug’s dosages, form, strengths, and more.

Sales of Otezla and Pomalyst are expanding rapidly at this biotech giant. Celgene Corp (CELG) is best known for Revlimid, a widely prescribed multiple myeloma therapy that saw sales jump 20% last ...

The answer is Pomalyst. Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year. And now it stands ready to ...

Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.

“Pomalyst has shown positive results in Kaposi sarcoma patients, regardless of their HIV status,” said Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch within the Center for ...

The answer is Pomalyst. Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year. And now it stands ready to ...